Professor Anne Rosser
Projects as PI
1 of 10
- A multi-center, open-label study evaluating the safety, tolerability and efficacy of pridopidine in patients with Huntington's disease (open PRIDE-HD) (09/05/2016 - 31/01/2018)
- A Multicenter, Randomized, Double-blind, Placebo controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease WVE-003-001 (01/11/2021 - 30/04/2023)
- A multi-centre, open-label study evaluating the safety, tolerability and efficacy of Pridopidine in patients with Huntington's disease (01/07/2016 - 30/06/2018)
- An open-label extension study to evaluate the long-term safety and tolerability of intrathecally administered R07234292 (RG6042) in patients with Huntington's disease (BN40955) (01/10/2019 - 31/03/2023)
- An open-label extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ISIS 443139 in Huntington's Disease patients who participated in prior investigational studies of ISIS 443139 (17/04/2018 - 30/04/2020)
Projects as Co-Investigator
1 of 11
- A comparative MRI study to determine the effect of extensive cognitive training on disease progression in HD (01/09/2012 - 28/02/2013)
- A device for delivering stem cell therapies to the human brain (15/05/2017 - 31/03/2018)
- Advanced pharmacological characterisation of a novel neuroprotective and cognitive enhancer drug for the treatment of neurodegenerative disorders (01/08/2018 - 31/12/2019)
- Advanced Therapies Trials (01/04/2025 - 31/03/2030)
- Advancing a stem cell therapy for Huntington’s disease towards the clinic (01/01/2024 - 30/06/2024)
